Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...

Johor is set to become Asia's largest insulin hub as India's leading biotechnology firm, Biocon Ltd, invests another RM1.1 ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Natural Biocon (India) Ltd - Outcome Of Meeting Of Independent Directors Held On March 21, 2025. Outcome of the meeting of Independent directors of the company held today to consider agendas as ...

Her remarks come amid discussions surrounding the NEP’s three-language policy, which encourages students to learn multiple ...

DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...

Nagaraj Shetti, Technical Research Analyst at HDFC Securities, believes Monday's pattern could be considered as a High Wave, ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

"Discover Civica Rx's plans for 2025, including launching new medications from their plant, expanding insulin program, and ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Biotechnology firm Biocon Ltd on Friday (March 7) said its subsidiary Biocon Biologics Ltd has announced positive results from its phase 3 clinical trial for Yesintek, a biosimilar to ustekinumab ...